Bone effects of hexarelin, a GH-releasing peptide, in female rats: influence of estrogen milieu.

Sibilia V, Cocchi D, Villa I, Lattuada N, Soglian A, Rubinacci A, Muller EE, Pecile A, Netti C

European journal of endocrinology1 Jun 2002Cited by 5 (Europe PMC)

PMID12039707DOI10.1530/eje.0.1460855PepBankPUB-12039707

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In intact middle-aged female rats, hexarelin did not modify urinary deoxypyridinoline excretion.
In plain wordsIn middle-aged female rats, hexarelin did not change a urine marker of bone breakdown.
Peptide
Hexarelin
Outcome
No significant changeUrinary Dpd excretion in intact rats
Study
ratn: not reported in source
intact 11-month-old female rats
Comparator
Saline-treated control rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg · s.c. · 60 daysAs given in this study (rat).
Source sentences
Summary
In intact rats, HEXA did not modify Dpd urinary excretion, induced a trend toward an increase of serum ALP activity and significantly increased BMC (+6.5%) and bone area (+4.1%) only at lumbar vertebrae.
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970701
02AnimalAnimal study (in vivo)Efficacy outcome
In intact middle-aged female rats, hexarelin induced a trend toward higher serum ALP activity without a significant change.
In plain wordsIn middle-aged female rats, hexarelin led to a non-significant trend toward higher serum ALP, a bone marker.
Peptide
Hexarelin
Outcome
No significant changeSerum ALP activity in intact rats
Study
ratn: not reported in source
intact 11-month-old female rats
Comparator
Saline-treated control rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg · s.c. · 60 daysAs given in this study (rat).
Source sentences
Summary
induced a trend toward an increase of serum ALP activity
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970702
03AnimalAnimal study (in vivo)Efficacy outcome
In intact middle-aged female rats, hexarelin significantly increased bone mineral content at lumbar vertebrae only.
In plain wordsIn middle-aged female rats, hexarelin increased bone mineral content in the lower spine only.
Peptide
Hexarelin
Outcome
IncreaseLumbar vertebrae BMC in intact rats
Study
ratn: not reported in source
intact 11-month-old female rats
Comparator
Saline-treated control rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg · s.c. · 60 daysAs given in this study (rat).
Measurements
BMC change
6.5%
lumbar vertebrae, intact rats
Source sentences
Summary
significantly increased BMC (+6.5%) and bone area (+4.1%) only at lumbar vertebrae
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970703
04AnimalAnimal study (in vivo)Efficacy outcome
In intact middle-aged female rats, hexarelin significantly increased bone area at lumbar vertebrae only.
In plain wordsIn middle-aged female rats, hexarelin increased bone area in the lower spine only.
Peptide
Hexarelin
Outcome
IncreaseLumbar vertebrae bone area in intact rats
Study
ratn: not reported in source
intact 11-month-old female rats
Comparator
Saline-treated control rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg · s.c. · 60 daysAs given in this study (rat).
Measurements
bone area change
4.1%
lumbar vertebrae, intact rats
Source sentences
Summary
significantly increased BMC (+6.5%) and bone area (+4.1%) only at lumbar vertebrae
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970704
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized middle-aged female rats, hexarelin did not modify the ovariectomy-induced increase in the bone turnover markers Dpd and ALP.
In plain wordsIn female rats with removed ovaries, hexarelin did not change the rise in bone turnover markers.
Peptide
Hexarelin
Outcome
No significant changeBone turnover markers in ovariectomized rats
Study
ratn: not reported in source
ovariectomized 11-month-old female rats
Comparator
Saline-treated control rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg · s.c. · 60 daysAs given in this study (rat).
Source sentences
Summary
In OVX rats, HEXA did not modify the OVX-induced increase in bone turnover markers (Dpd and ALP)
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970705
06AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized middle-aged female rats, hexarelin did not affect the ovariectomy-induced vertebral bone loss.
In plain wordsIn female rats with removed ovaries, hexarelin did not stop bone loss in the spine.
Peptide
Hexarelin
Outcome
No significant changeVertebral bone loss in ovariectomized rats
Study
ratn: not reported in source
ovariectomized 11-month-old female rats
Comparator
Saline-treated control rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg · s.c. · 60 daysAs given in this study (rat).
Source sentences
Summary
and did not affect the OVX-induced vertebral bone loss
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970706
07AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized middle-aged female rats, hexarelin significantly increased bone mineral content at femoral mid-diaphyses.
In plain wordsIn female rats with removed ovaries, hexarelin increased bone mineral content in the middle of the thigh bone.
Peptide
Hexarelin
Outcome
IncreaseFemoral mid-diaphysis BMC in ovariectomized rats
Study
ratn: not reported in source
ovariectomized 11-month-old female rats
Comparator
Saline-treated control rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg · s.c. · 60 daysAs given in this study (rat).
Measurements
BMC change
7.2%
femoral mid-diaphyses, OVX rats
Source sentences
Summary
but significantly increased BMC (+7.2%) and bone area (+5.3%) at femoral mid-diaphyses
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970707
08AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized middle-aged female rats, hexarelin significantly increased bone area at femoral mid-diaphyses.
In plain wordsIn female rats with removed ovaries, hexarelin increased bone area in the middle of the thigh bone.
Peptide
Hexarelin
Outcome
IncreaseFemoral mid-diaphysis bone area in ovariectomized rats
Study
ratn: not reported in source
ovariectomized 11-month-old female rats
Comparator
Saline-treated control rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 microg/kg · s.c. · 60 daysAs given in this study (rat).
Measurements
bone area change
5.3%
femoral mid-diaphyses, OVX rats
Source sentences
Summary
but significantly increased BMC (+7.2%) and bone area (+5.3%) at femoral mid-diaphyses
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970708
09AnimalAnimal study (in vivo)Efficacy outcome
In intact and ovariectomized middle-aged female rats, hexarelin significantly increased serum IGF-I at day 14.
In plain wordsIn middle-aged female rats, hexarelin raised IGF-I at day 14.
Peptide
Hexarelin
Outcome
IncreaseSerum IGF-I at day 14
Study
ratn: not reported in source
intact and ovariectomized 11-month-old female rats
Comparator
Saline-treated control rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 microg/kg · s.c. · 14 daysAs given in this study (rat).
Source sentences
Summary
HEXA significantly increased serum IGF-I levels at day 14, but not at day 60, in both intact and OVX rats
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970709
10AnimalAnimal study (in vivo)Efficacy outcome
In intact and ovariectomized middle-aged female rats, hexarelin did not significantly increase serum IGF-I at day 60.
In plain wordsIn middle-aged female rats, hexarelin did not raise IGF-I at day 60.
Peptide
Hexarelin
Outcome
No significant changeSerum IGF-I at day 60
Study
ratn: not reported in source
intact and ovariectomized 11-month-old female rats
Comparator
Saline-treated control rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 microg/kg · s.c. · 60 daysAs given in this study (rat).
Source sentences
Summary
HEXA significantly increased serum IGF-I levels at day 14, but not at day 60, in both intact and OVX rats
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970710
11AnimalAnimal study (in vivo)Efficacy outcome
In middle-aged female rats, the GH secretory response to hexarelin was higher in intact than in ovariectomized rats.
In plain wordsIn middle-aged female rats, hexarelin caused a larger growth hormone release in intact rats than in rats with removed ovaries.
Peptide
Hexarelin
Outcome
MixedGH secretory response to hexarelin in intact versus ovariectomized rats
Study
ratn: not reported in source
intact and ovariectomized 11-month-old female rats
Comparator
Ovariectomized versus intact rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 microg/kg · s.c. · 60 daysAs given in this study (rat).
Source sentences
Summary
whereas the GH secretory response to HEXA was higher in the former than in the latter.
1 context sentence(design, population, supporting numbers)
Summary · context
HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated with respect to those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered is…
Report a problemFND-1203970711

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.